Graphite Bio, Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…
Macro
US · Macroeconomic Factors/Risks · ForecastsGraphite Bio, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)
Likelihood Legend A++ is best, F- worst
- A++
- A+
- A
-
Very Unlikely - B+
- B
-
Unlikely
- C+
- C
- D+
- D
- D-
-
Avg.
- E+
- E-
-
Unlikely - F+
- F
- F-
-
Very Unlikely
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.